Computational & Systems Biology Program
The Dana Pe'er Lab
The Pe’er lab combines single cell technologies, genomic datasets and machine learning algorithms to address fundamental questions in biomedical science. Empowered by recent breakthrough technologies like massive parallel single cell RNA-sequencing, we ask questions such as: How do multi-cellular organisms develop from a single cell, resulting in the vast diversity of progenitor and terminal cell types? How does a cell’s regulatory circuit control the dynamics of signal processing and how do these circuits rewire over the course of development? How does an ensemble of cells function together to execute a multi-cellular response, such as an immune response to pathogen or cancer? We will also address more medically oriented questions such as: How do regulatory circuits go awry in disease? What is the consequence of intra-tumor heterogeneity? Can we characterize the tumor immune eco-system to gain a better understanding of when or why immunotherapy works or does not work? A key goal is to use this characterization of the tumor immune eco-system to personalize immunotherapy.
The emergent landscape of the mouse gut endoderm at single-cell resolution. Nowotschin S, Setty M, Kuo YY, Liu V, Garg V, Sharma R, Simon CS, Saiz N, Gardner R, Boutet SC, Church DM, Hoodless PA, Hadjantonakis AK, Pe’er D. Nature. 2019 May;569(7756):361-367. doi: 10.1038/s41586-019-1127-1. Epub 2019 Apr 8. PMID: 30959515
Characterization of cell fate probabilities in single-cell data with Palantir. Setty M, Kiseliovas V, Levine J, Gayoso A, Mazutis L, Pe’er D. Nat Biotechnol. 2019 Apr;37(4):451-460. doi: 10.1038/s41587-019-0068-4. PMID: 30899105.
Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, Nainys J, Wu K, Kiseliovas V, Setty M, Choi K, Fromme RM, Dao P, McKenney PT, Wasti RC, Kadaveru K, Mazutis L, Rudensky AY, Pe’er D. Cell. 2018 Aug 23;174(5):1293-1308.e36. doi: 10.1016/j.cell.2018.05.060. PMID: 29961579
Dana Pe'er, PhD
Chair, Computational and Systems Biology Program, SKI; Scientific Director, Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center
- Computational Biologist Dana Pe’er combines single cell technologies, genomic datasets and machine learning techniques to address fundamental questions addressing regulatory cell circuits, cellular development, tumor immune eco-system, genotype to phenotype relations and precision medicine.
- PhD, Hebrew University, Jerusalem Israel
- [email protected]
- Email Address
- PhD, University of Paris – XI / Institute Gustave Roussy, France (Oncology)
- BS, Évry Val d’Essonne University, France (Cellular Biology and Physiology)
- PhD in Computational Biology, Cornell University, Ithaca NY USA
- Minor: Computer Science (Concentration: Machine learning)
- BSc in Biochemistry, The Chinese University of Hong Kong, Hong Kong
- PhD, University of Cambridge, UK (Medical Sciences)
- MSc, University of York, UK (Computational Biology and Bioinformatics)
- BSc, Universidad Nacional Autónoma de México, Mexico (Biomedicine)
- MS, Drexel University (Biomedical Science), Philadelphia, USA, 2016 Concentration: BioMEMS, Biomaterials & Tissue Engineering
- BSc, Pokhara University (Medical Laboratory Technology), Kathmandu, Nepal, 2011
- PhD, Francis Crick Institute/Imperial College London (Computational Biology)
- MSc, University of Warwick (Mathematics of Complex Systems)
- MMath, University of Warwick (Mathematics)
- PhD, Weill Cornell Graduate School, New York (Systems Biology)
- MS, Columbia University, New York (Computer Science)
- BEng, National Institute of Technology, Karnataka, India (Computer Engineering)
- 2014 NIH Director’s Pioneer Award
- 2014 ISCB Overton Prize
- 2012 RECOMB 2012 Test of Time Award
- 2010 SU2C AACR Innovator award
- 2009 Packard Fellowship in Science and Engineering
- 2007 NIH Directors New Innovator Award
- 2005 Runner up for “Breakthrough of the year”, Science Magazine
- 2005 Career Award at the Interface of Science, Burroughs Welcome Fund
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Dana Pe'er discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.